Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, the project will finance Promoter's expenditures in Research, Development and Innovation (RDI) in its portfolio of biosimilars, generic drugs, infusion therapies, clinical nutrition products and the devices for administering these products as well as capacity expansion investments in existing facilities.
The aim is to support the promoter's RDI investments to advance its development of Pharma, Biopharma, Nutrition and MedTech products. The project also includes capital expenditure (capex).
The financing of the Project supports EU objectives of Research, Development and Innovation, as well as the strengthening of the EU's pharmaceutical manufacturing resilience. R&D activities generate significant positive knowledge and technology externalities, through the creation of innovative processes, products and services and through skills development and upgrading. Moreover, it supports the increase of manufacturing capacity of medicinal products in the EU, including critical medicines. The EIB will support the Promoter, a pharmaceutical/ medical device and biologics manufacturer, to execute its investment programme encompassing (i) the development of a pipeline of biosimilars and generics medicines and (ii) the expansion of its manufacturing footprint in the EU.
The Promoter is a knowledge-based company developing innovative therapies and treatments for life threatening diseases addressing unmet medical needs. The company's R&D intensity is above the sector average contributing positively to the EU's 3% R&D intensity target. By supporting the Promoter, the EIB enables the generation of European scientific knowledge and acumen, whilst preserving highly skilled employment opportunities. Moreover, it contributes to the reduction of supply chain risks for medicinal products in the EU and to the improvement the access to and affordability of medicinal treatments. EIB involvement will help ensure that the important benefits of bringing novel therapies and medical devices to the patients in a timely manner.
The Bank's contribution to the Project stems from its large-scale support to the diversification of the Borrower's financing sources combined with the flexible drawdown terms and longer availability. This enables the Bank to act as an anchor investor, thereby facilitating the Project's financing and full implementation.
According to the Environmental and Social Data Sheet, the investments take place in existing facilities without a significant negative environmental impact.
Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE; OTC: FSNUY) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs.
| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | FRESENIUS SE & CO KGAA | Client | - |
Contact: Richard Willis
Email: r.willis@eib.org
Phone: + 352 4379 – 82155
ACCESS TO INFORMATION
You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm
ACCOUNTABILITY MECHANISM OF EIB
The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf
When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces
